Clinical Trial Update: Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial evaluating a dopamine D1 receptor agonist for cognitive enhancement in schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• D1 receptor agonist (investigational)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Schizophrenia, Schizoaffective Disorder | EARLY_Phase 1 | Status: COMPLETED